JP2001288035A - External preparation for skin for acne - Google Patents
External preparation for skin for acneInfo
- Publication number
- JP2001288035A JP2001288035A JP2000098285A JP2000098285A JP2001288035A JP 2001288035 A JP2001288035 A JP 2001288035A JP 2000098285 A JP2000098285 A JP 2000098285A JP 2000098285 A JP2000098285 A JP 2000098285A JP 2001288035 A JP2001288035 A JP 2001288035A
- Authority
- JP
- Japan
- Prior art keywords
- acne
- extract
- singlet oxygen
- skin
- external preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 63
- 206010000496 acne Diseases 0.000 title claims abstract description 63
- 238000002360 preparation method Methods 0.000 title claims abstract description 57
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims abstract description 72
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract description 17
- 229940121363 anti-inflammatory agent Drugs 0.000 claims abstract description 17
- 239000012190 activator Substances 0.000 claims abstract description 14
- 239000000284 extract Substances 0.000 claims description 46
- 229940123973 Oxygen scavenger Drugs 0.000 claims description 26
- 230000002000 scavenging effect Effects 0.000 claims description 25
- 230000000844 anti-bacterial effect Effects 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 239000003899 bactericide agent Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 239000007844 bleaching agent Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 4
- 241000238366 Cephalopoda Species 0.000 claims description 3
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims description 2
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 2
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 claims description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 2
- 244000269722 Thea sinensis Species 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims description 2
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 2
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims description 2
- 235000013793 astaxanthin Nutrition 0.000 claims description 2
- 229940022405 astaxanthin Drugs 0.000 claims description 2
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 2
- 239000001168 astaxanthin Substances 0.000 claims description 2
- 235000013734 beta-carotene Nutrition 0.000 claims description 2
- 239000011648 beta-carotene Substances 0.000 claims description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 2
- 229960002747 betacarotene Drugs 0.000 claims description 2
- 229940008396 carrot extract Drugs 0.000 claims description 2
- 229960003067 cystine Drugs 0.000 claims description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 2
- 239000004318 erythorbic acid Substances 0.000 claims description 2
- 235000010350 erythorbic acid Nutrition 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 claims description 2
- 229940026239 isoascorbic acid Drugs 0.000 claims description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 235000005875 quercetin Nutrition 0.000 claims description 2
- 229960001285 quercetin Drugs 0.000 claims description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 2
- 235000005493 rutin Nutrition 0.000 claims description 2
- 229960004555 rutoside Drugs 0.000 claims description 2
- SHWIJIJNPFXOFS-UHFFFAOYSA-N thiotaurine Chemical compound NCCS(O)(=O)=S SHWIJIJNPFXOFS-UHFFFAOYSA-N 0.000 claims description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 235000010930 zeaxanthin Nutrition 0.000 claims description 2
- 229940043269 zeaxanthin Drugs 0.000 claims description 2
- 239000001775 zeaxanthin Substances 0.000 claims description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 2
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 claims 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical group O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 21
- 230000003405 preventing effect Effects 0.000 abstract description 11
- 238000013329 compounding Methods 0.000 abstract description 8
- 230000003449 preventive effect Effects 0.000 abstract description 4
- 230000002910 effect on acne Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 44
- 238000012360 testing method Methods 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 239000000839 emulsion Substances 0.000 description 13
- 230000002265 prevention Effects 0.000 description 12
- -1 packs Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 7
- 150000004032 porphyrins Chemical class 0.000 description 7
- 230000002087 whitening effect Effects 0.000 description 7
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 6
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 239000000419 plant extract Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229940031439 squalene Drugs 0.000 description 4
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 3
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 229960003720 enoxolone Drugs 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 description 3
- 239000001685 glycyrrhizic acid Substances 0.000 description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 3
- 235000019410 glycyrrhizin Nutrition 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000011787 zinc oxide Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 2
- 240000006891 Artemisia vulgaris Species 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 229940069521 aloe extract Drugs 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 235000020221 chamomile extract Nutrition 0.000 description 2
- 229940119217 chamomile extract Drugs 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229960000735 docosanol Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 229940069445 licorice extract Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 2
- 229960001755 resorcinol Drugs 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- AFDXODALSZRGIH-QPJJXVBHSA-N (E)-3-(4-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC=C(\C=C\C(O)=O)C=C1 AFDXODALSZRGIH-QPJJXVBHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000272185 Falco Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 240000000691 Houttuynia cordata Species 0.000 description 1
- 235000013719 Houttuynia cordata Nutrition 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 235000017879 Nasturtium officinale Nutrition 0.000 description 1
- 240000005407 Nasturtium officinale Species 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940038487 grape extract Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000010330 ougon Substances 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- AFDXODALSZRGIH-UHFFFAOYSA-N p-coumaric acid methyl ether Natural products COC1=CC=C(C=CC(O)=O)C=C1 AFDXODALSZRGIH-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229960005349 sulfur Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、にきび用皮膚外用
剤に関し、更に詳細には、一定以上の一重項酸素消去能
力を奏する量の一重項酸素消去剤を含有することによ
り、にきびの予防や改善に有効なにきび用皮膚外用剤に
関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an external preparation for acne and, more particularly, to a method for preventing acne by containing an amount of a singlet oxygen scavenger having a certain amount of singlet oxygen scavenging ability. The present invention relates to a skin external preparation for acne which is effective for improvement.
【0002】[0002]
【従来の技術】にきびは、尋常性座瘡とも呼ばれ、毛孔
に一致して丘疹あるいは膿疱の生じる現象をいう。にき
びは、特に思春期、青年期の男女の、顔面等に生じるも
のであるため、その予防や改善が強く求められている。
このため、にきびを予防、改善するための皮膚外用剤、
例えば、乳液、クリーム、化粧水、パック、洗浄料、分
散液、軟膏、外用液剤等が数多く提供されている。2. Description of the Related Art Acne is also called acne vulgaris, and refers to a phenomenon in which papules or pustules occur in accordance with pores. Since acne occurs particularly on the face of men and women during adolescence and adolescence, prevention and improvement of acne are strongly demanded.
For this reason, skin external preparations for preventing and improving acne,
For example, many emulsions, creams, lotions, packs, detergents, dispersions, ointments, external preparations, and the like are provided.
【0003】これらの皮膚外用剤には、にきびを予防ま
たは改善するための成分として、従来からグリチリチン
酸やグリチルレチン酸及びそれらの誘導体などの抗炎症
剤やイオウ、レゾルシンなどの殺菌剤が用いられてき
た。[0003] In these skin external preparations, anti-inflammatory agents such as glycyrrhizic acid, glycyrrhetinic acid and derivatives thereof, and bactericides such as sulfur and resorcinol have been conventionally used as components for preventing or improving acne. Was.
【0004】[0004]
【発明が解決しようとする課題】しかしながら、これら
の抗炎症剤や殺菌剤は、にきびの予防や改善効果が十分
でなかったり、あるいは、製剤中で変質するなどして所
期の薬効が得られない場合が多かった。従って、にきび
の予防や改善効果が優れた薬剤を見出し、これを配合し
たにきび用皮膚外用剤の提供が望まれていた。However, these anti-inflammatory agents and bactericides do not have sufficient acne prevention or amelioration effects, or have the desired medicinal effects due to deterioration in the preparation. Often not. Therefore, it has been desired to find a drug excellent in the effect of preventing and improving acne, and to provide a skin external preparation for acne containing the drug.
【0005】[0005]
【課題を解決するための手段】本発明者らは、にきびに
関連する因子を種々探求していたところ、にきびの発症
に一重項酸素が大きく関与していることを突き止めた。
そして、皮膚外用剤に所定以上の一重項酸素消去能力と
なる量の一重項酸素消去剤を配合すれば、にきび予防及
び改善効果を著しく向上させることができることおよ
び、更にこの一重項酸素消去剤に紫外線防止剤や美白
剤、抗炎症剤、殺菌剤、細胞賦活剤等の薬剤を組み合わ
せれば、より高いにきび予防及び改善効果が得られるこ
とを見出し本発明を完成した。Means for Solving the Problems The present inventors have searched for various factors related to acne, and have found that singlet oxygen is greatly involved in the development of acne.
If the amount of the singlet oxygen scavenger having the predetermined or higher singlet oxygen scavenging ability is added to the external preparation for skin, the acne prevention and improvement effects can be significantly improved, and furthermore, the singlet oxygen scavenger can be added to this singlet oxygen scavenger. The present inventors have found that higher acne prevention and improvement effects can be obtained by combining agents such as an ultraviolet ray inhibitor, a whitening agent, an anti-inflammatory agent, a bactericide, and a cell activator, and completed the present invention.
【0006】すなわち本発明は、一重項酸素消去能力と
して50s−1以上となる量の一重項酸素消去剤を含有
することを特徴とするにきび用皮膚外用剤を提供するも
のである。That is, the present invention provides an external preparation for acne characterized in that it contains an amount of a singlet oxygen scavenger having a singlet oxygen scavenging ability of 50 s -1 or more.
【0007】また本発明は、次の成分(A)及び(B) (A)一重項酸素消去能力として50s−1以上となる
量の一重項酸素消去剤 (B)紫外線防止剤の一種又は二種以上を含有すること
を特徴とするにきび用皮膚外用剤を提供するものであ
る。The present invention also relates to the following components (A) and (B): (A) a singlet oxygen scavenger having a singlet oxygen scavenging capacity of 50 s -1 or more; It is intended to provide a skin external preparation for acne characterized by containing at least one species.
【0008】更に本発明は、上記にきび用皮膚外用剤に
成分(C) (C)美白剤、抗炎症剤、殺菌剤および細胞賦活剤から
選ばれる薬剤の一種又は二種以上を含有するにきび用皮
膚外用剤を提供するものである。[0008] The present invention further provides a composition for acne, wherein the external preparation for acne contains one or more components selected from the group consisting of component (C) (C) a whitening agent, an anti-inflammatory agent, a bactericide and a cell activator. A skin external preparation is provided.
【0009】[0009]
【発明の実施の形態】本発明において用いられる一重項
酸素消去剤としては、一重項酸素を有効に消去すること
ができ、皮膚外用剤に添加した場合に特段の問題を生じ
ない化合物を含むものであれば特に限定なく使用するこ
とができる。この一重項酸素消去剤として作用する化合
物は、どのような測定方法によってスクリーニングして
もよいが、例えば一重項酸素検出装置(特開平7−15
9325号)を用いることにより、容易にスクリーニン
グすることができる。BEST MODE FOR CARRYING OUT THE INVENTION The singlet oxygen scavenger used in the present invention contains a compound which can effectively scavenge singlet oxygen and does not cause any particular problem when added to an external preparation for skin. If it is, it can be used without particular limitation. The compound acting as a singlet oxygen scavenger may be screened by any measurement method. For example, a singlet oxygen detector (JP-A-7-15)
9325) can be easily screened.
【0010】本発明において、一重項酸素消去剤の有効
成分として利用される化合物の具体例としては、ルチン
およびその誘導体、クエルセチン、β−カロチン、アス
タキサンチン、ゼアキサンチン、ビタミンE及びその誘
導体並びにそれらの塩、エリソルビン酸、ヒスチジン、
トリプトファン、チロシン、メチオニン、シスチン、ヒポタ
ウリン、チオタウリン、ニンジン抽出物、マイカイカ抽出
物、サンペンズ抽出物、メリッサ抽出物、ヤシャジツ抽
出物、羅漢果抽出物、茶抽出物、リン脂質等が挙げられ
る。In the present invention, specific examples of the compound used as an active ingredient of the singlet oxygen scavenger include rutin and derivatives thereof, quercetin, β-carotene, astaxanthin, zeaxanthin, vitamin E and derivatives thereof, and salts thereof. , Erythorbic acid, histidine,
Examples include tryptophan, tyrosine, methionine, cystine, hypotaurine, thiotaurine, carrot extract, squid extract, sampens extract, melissa extract, yasajitsu extract, arhat extract, tea extract, and phospholipid.
【0011】本発明のにきび用皮膚外用剤における、一
重項酸素消去剤の含有量は、その一重項酸素消去能力と
して50s−1以上となる量であることが必要である。
すなわち、一重項酸素消去剤の有効成分である化合物
は、それぞれ重量またはモル当たりの反応速度定数が決
まっているが、この反応速度定数と配合濃度をかけて得
られる一重項酸素消去能力を50s−1以上にすること
が重要である。特にこの値を1000s−1以上とすれ
ば、より優れたにきび予防及び改善効果が得られる。[0011] The content of the singlet oxygen scavenger in the external preparation for acne of the present invention must be 50 s- 1 or more as its singlet oxygen scavenging ability.
That is, the compound which is the active ingredient of the singlet oxygen scavenger has a reaction rate constant per weight or mole, and the singlet oxygen scavenging ability obtained by multiplying the reaction rate constant and the compounding concentration is 50 s −. it is important to 1 or more. Particularly when this value is 1000 s −1 or more, more excellent acne prevention and improvement effects can be obtained.
【0012】上記の一重項酸素消去剤は、これをにきび
の予防または改善成分とし、常法に従って通常の皮膚外
用剤に使用される種々の形態の基剤に配合し、製剤化す
ることによりにきび用皮膚外用剤を得ることができる
が、更に紫外線防止剤や他の薬効成分と組み合わせるこ
とにより、より効果の優れたにきび用皮膚外用剤が得ら
れる。The above singlet oxygen scavenger is used as a component for preventing or ameliorating acne, and is mixed with various types of bases used in ordinary skin external preparations in accordance with a conventional method to prepare acne. An external preparation for skin can be obtained, but by further combining it with an ultraviolet ray inhibitor and other medicinal ingredients, a skin external preparation for acne having more excellent effects can be obtained.
【0013】本発明において、一重項酸素消去剤
((A)成分)と組合せ使用される紫外線防止剤
((B)成分)としては、パラメトキシケイ皮酸−2−
エチルヘキシル、オキシベンゾン、4−tert−ブチ
ル−4'−メトキシジベンゾイルメタン、酸化チタン、
微粒子酸化チタン、酸化亜鉛等が挙げられる。これらの
紫外線防止剤のうち、特に好ましいものとしては、パラ
メトキシケイ皮酸−2−エチルヘキシル、酸化チタン、
微粒子酸化チタン、酸化亜鉛が挙げられる。In the present invention, the UV inhibitor (component (B)) used in combination with the singlet oxygen scavenger (component (A)) includes paramethoxycinnamic acid-2-.
Ethylhexyl, oxybenzone, 4-tert-butyl-4′-methoxydibenzoylmethane, titanium oxide,
Fine particle titanium oxide, zinc oxide and the like can be mentioned. Of these UV inhibitors, particularly preferred are 2-ethylhexyl paramethoxycinnamate, titanium oxide,
Fine particle titanium oxide and zinc oxide are exemplified.
【0014】一方、他の薬効成分((C)成分)として
は、美白剤、抗炎症剤、殺菌剤、細胞賦活剤から選ばれ
るものであるが、具体的な薬効剤の例としては、それぞ
れ以下に示すものが挙げられる。On the other hand, the other medicinal component (component (C)) is selected from a whitening agent, an anti-inflammatory agent, a bactericide and a cell activator. The following are mentioned.
【0015】( 美白剤 )美白剤としては、ビタミン
C及びその誘導体並びにそれらの塩、胎盤抽出物、甘草
抽出物、ヨクイニン抽出物、オウゴン抽出物、海藻抽出
物、ビャクレン抽出物、センプクカ抽出物、ブドウ抽出
物、コムギ抽出物、トマト抽出物等が挙げられる。(Whitening Agents) As whitening agents, vitamin C and its derivatives and salts thereof, placenta extract, licorice extract, yokunin extract, gongo extract, seaweed extract, syllable extract, sempukuka extract, Grape extract, wheat extract, tomato extract and the like.
【0016】これらの美白剤のうち、特に好ましいもの
としては、ビタミンC及びその誘導体並びにそれらの
塩、胎盤抽出物が挙げられる。Among these whitening agents, particularly preferred are vitamin C and its derivatives, salts thereof, and placental extracts.
【0017】( 抗炎症剤 )抗炎症剤としては、グリチ
ルリチン酸、グリチルレチン酸及びそれらの誘導体並び
にそれらの塩、アロエ抽出物、シソ抽出物、ヨモギ抽出
物、カミツレ抽出物、コンフリー抽出物、ジユ抽出物、
クレソン抽出物、オウバク抽出物等が挙げられる。(Anti-inflammatory agent) As the anti-inflammatory agent, glycyrrhizic acid, glycyrrhetinic acid and their derivatives and their salts, aloe extract, perilla extract, mugwort extract, chamomile extract, comfrey extract, diuretic extract Extract,
Watercress extract, oak extract and the like.
【0018】これらの抗炎症剤のうち、特に好ましいも
のとしては、グリチルリチン酸、グリチルレチン酸及び
それらの誘導体並びにそれらの塩が挙げられる。Of these anti-inflammatory agents, particularly preferred are glycyrrhizic acid, glycyrrhetinic acid and their derivatives and salts thereof.
【0019】( 殺菌剤 )殺菌剤としてはイオウ、レ
ゾルシン、サリチル酸、イソプロピルメチルフェノー
ル、塩化ベンザルコニウム、ヒノキチオール、ドクダミ
抽出物、クララ抽出物等が挙げられる。(Disinfectant) Disinfectants include sulfur, resorcin, salicylic acid, isopropylmethylphenol, benzalkonium chloride, hinokitiol, dokudami extract, Clara extract and the like.
【0020】これらの殺菌剤のうち、特に好ましいもの
としてはイオウ、サリチル酸、イソプロピルメチルフェ
ノールが挙げられる。Of these fungicides, particularly preferred are sulfur, salicylic acid, and isopropylmethylphenol.
【0021】( 細胞賦活剤 )細胞賦活剤としては、ビ
タミンA及びその誘導体、クエン酸、乳酸、酒石酸、リ
ンゴ酸、グリコール酸、コハク酸、セリン、グルタミン
酸、ヒドロキシプロリン、テアニン、ピロリドンカルボ
ン酸、酵母、乳酸菌およびビフィズス菌の醗酵代謝物等
が挙げられる。(Cell activator) Cell activators include vitamin A and its derivatives, citric acid, lactic acid, tartaric acid, malic acid, glycolic acid, succinic acid, serine, glutamic acid, hydroxyproline, theanine, pyrrolidone carboxylic acid, yeast , Lactic acid bacteria and bifidobacteria.
【0022】これらの細胞賦活剤のうち、特に好ましい
ものとしては、ビタミンA及びその誘導体、クエン酸、
リンゴ酸、乳酸、セリン、ピロリドンカルボン酸が挙げ
られる。Among these cell activators, particularly preferred are vitamin A and its derivatives, citric acid,
Malic acid, lactic acid, serine, and pyrrolidone carboxylic acid are included.
【0023】本発明の皮膚外用剤における上記(B)成
分の紫外線防止剤および(C)成分の薬効剤の配合量
は、それぞれの種類により相違するが、以下に示す範囲
とすることが好ましい。この範囲であれば、(A)成分
の一重項酸素消去剤と組み合わせた場合、製剤及び製剤
中の(A)成分の一重項酸素消去剤の経時安定性に影響
を及ぼすことがなく、より高いにきび予防及び改善効果
を発揮させることができる。The amounts of the ultraviolet ray preventive component (B) and the efficacious agent (C) in the external preparation for skin of the present invention vary depending on the type of the agent, but are preferably in the following ranges. Within this range, when combined with the singlet oxygen scavenger of the component (A), the stability over time of the preparation and the singlet oxygen scavenger of the component (A) in the preparation is not affected and is higher. Acne prevention and improvement effects can be exerted.
【0024】すなわち、本発明における(B)成分の配
合量としては、好ましくは0.001〜20質量%(以
下、単に「%」で示す)、より好ましくは0.01〜1
0%の範囲である。この範囲であればより優れた紫外線
防止効果が発現し、かつ、優れたにきび予防及び改善効
果を示す皮膚外用剤が得られる。That is, the compounding amount of the component (B) in the present invention is preferably 0.001 to 20% by mass (hereinafter simply referred to as "%"), and more preferably 0.01 to 1% by mass.
The range is 0%. Within this range, a skin external preparation that exhibits a more excellent ultraviolet ray preventing effect and also has an excellent acne prevention and improvement effect can be obtained.
【0025】一方、本発明の(C)成分のうち美白剤の
配合量は、好ましくは0.00001〜10%であり、
より好ましくは0.0001〜5%の範囲である。胎盤
抽出物及び植物抽出物を抽出液のまま用いる場合は乾燥
固形分としてこの範囲であれば問題ない。この範囲であ
ればより優れたにきび予防及び改善効果を示す皮膚外用
剤が得られる。On the other hand, the blending amount of the whitening agent in the component (C) of the present invention is preferably 0.0001 to 10%,
More preferably, it is in the range of 0.0001 to 5%. When the placenta extract and the plant extract are used as they are, there is no problem as long as the dry solid content is within this range. Within this range, an external preparation for skin exhibiting more excellent acne prevention and improvement effects can be obtained.
【0026】また、本発明の(C)成分のうち抗炎症剤
の配合量は、0.00001〜5%の範囲が好ましく、
より好ましくは0.0001〜3%の範囲である。植物
抽出物を抽出液のまま用いる場合は乾燥固形分としてこ
の範囲であれば問題ない。この範囲であれば優れた抗炎
症効果がみられ、かつ、優れたにきび予防及び改善効果
を示す皮膚外用剤が得られる。In addition, the amount of the anti-inflammatory agent in the component (C) of the present invention is preferably in the range of 0.0001 to 5%,
More preferably, it is in the range of 0.001 to 3%. When the plant extract is used as it is, there is no problem as long as the dry solid content is within this range. Within this range, an external preparation for skin that exhibits excellent anti-inflammatory effects and excellent acne prevention and improvement effects can be obtained.
【0027】更に、本発明の(C)成分のうち殺菌剤の
配合量は0.00001〜5%の範囲が好ましく、より
好ましくは0.0001〜3%の範囲である。植物抽出
物を抽出液のまま用いる場合は乾燥固形分としてこの範
囲であれば問題ない。この範囲であれば優れた殺菌効果
がみられ、かつ、優れたにきび予防及び改善効果を示す
皮膚外用剤が得られる。Further, among the component (C) of the present invention, the amount of the bactericide is preferably in the range of 0.0001 to 5%, more preferably in the range of 0.001 to 3%. When the plant extract is used as it is, there is no problem as long as the dry solid content is within this range. Within this range, an external preparation for skin which exhibits excellent bactericidal effects and excellent acne prevention and improvement effects can be obtained.
【0028】更にまた、本発明の(C)成分である細胞
賦活剤の配合量は、好ましくは0.00001〜5%、
より好ましくは0.0001〜3%の範囲である。この
範囲であればより優れた肌荒れ改善効果が発現し、か
つ、優れたにきび予防及び改善効果を示す皮膚外用剤が
得られる。Furthermore, the compounding amount of the cell activator (C) of the present invention is preferably 0.0001 to 5%,
More preferably, it is in the range of 0.001 to 3%. Within this range, a skin external preparation that exhibits a more excellent effect of improving skin roughness and that exhibits an excellent effect of preventing and improving acne can be obtained.
【0029】本発明のにきび用皮膚外用剤の製造に当た
っては、(B)成分である紫外線防止剤と(C)成分で
ある薬効剤(美白剤、抗炎症剤、殺菌剤および細胞賦活
剤)は、これらを組合せて使用することができ、また、
それぞれの成分中で複数の化合物ないしは薬効剤を配合
することもできる。更に、(C)成分の薬効剤である美
白剤、抗炎症剤、殺菌剤および細胞賦活剤も、それぞれ
から複数の化合物を選択し、二種以上組み合わせて用い
ることもできる。In producing the external acne preparation for acne of the present invention, the ultraviolet ray preventive agent as the component (B) and the medicinal agents (whitening agent, anti-inflammatory agent, bactericide and cell activator) as the component (C) are used. , Can be used in combination,
A plurality of compounds or medicinal agents can be blended in each component. Further, a plurality of compounds may be selected from each of the whitening agents, anti-inflammatory agents, bactericides, and cell activators which are the active ingredients of the component (C), and two or more compounds may be used in combination.
【0030】本発明の成分(A)に、成分(B)および
/または成分(C)を組み合わせた皮膚外用剤は、常法
に従い、これら各成分を通常の皮膚外用剤として知られ
る種々の形態の基剤に配合して調製することができる。
この場合における成分(A)の配合量も、前記したよう
にその一重項酸素消去能力として50s−1以上となる
量であることが必要である。The external preparation for skin obtained by combining the component (A) with the component (B) and / or the component (C) according to the present invention can be prepared by various methods known in the art according to a conventional method. Can be prepared by blending in the base.
In this case, the compounding amount of the component (A) also needs to be such that the singlet oxygen scavenging ability is 50 s −1 or more as described above.
【0031】かくして得られるにきび用皮膚外用剤の配
合形態は、特に限定されず、例えば、乳液、クリーム、
化粧水、パック、洗浄料、メーキャップ化粧料、分散
液、軟膏などの化粧料や外用医薬品等とすることができ
る。The formulation of the external preparation for acne skin thus obtained is not particularly limited, and examples thereof include emulsions, creams,
It can be used as cosmetics such as lotions, packs, cleaning agents, makeup cosmetics, dispersions, ointments, and external medicines.
【0032】そして、上記皮膚外用剤の形態に応じ、前
記必須成分以外に通常化粧品や医薬品等の皮膚外用剤に
用いられる成分、例えば、精製水、低級アルコール、多
価アルコール、油性成分、粉体、界面活性剤、増粘剤、
色材、防腐剤、保湿剤、香料等を用いることができる。Depending on the form of the above-mentioned external preparation for skin, other than the above-mentioned essential components, components usually used in external preparations for skin such as cosmetics and pharmaceuticals, for example, purified water, lower alcohols, polyhydric alcohols, oily components, powders , Surfactants, thickeners,
Coloring materials, preservatives, humectants, fragrances and the like can be used.
【0033】[0033]
【作用】本発明は、にきびの発症に一重項酸素が大きく
関与しているという新規な知見に基づくものである。す
なわち、皮脂を作り出す器官である皮脂腺には、アクネ
菌(Propioniobacterium acnes)が棲息しており、アクネ
菌は代謝産物としてポルフィリン類を産生し、菌体外に
排出する。本発明者らの研究により、このポルフィリン
は皮脂の分泌とともに皮膚表面に排出されることが明ら
かになった。そして、皮膚表面に排出されたポルフィリ
ンに紫外線があたると、活性酸素の一種であり非常に反
応性の高い一重項酸素が発生することを、我々の開発し
た一重項酸素検出装置(特開平7−159325号)を
用いることにより直接検出した。The present invention is based on a novel finding that singlet oxygen is greatly involved in the onset of acne. That is, acne bacteria ( Propioniobacterium acnes ) inhabit sebaceous glands, which are organs that produce sebum, and acne bacteria produce porphyrins as metabolites and excrete them outside the cells. Our studies have revealed that this porphyrin is excreted on the skin surface together with the secretion of sebum. When a porphyrin discharged on the skin surface is irradiated with ultraviolet rays, singlet oxygen, which is a kind of active oxygen and is highly reactive, is generated. No. 159325).
【0034】また、皮膚表面にある表皮脂質が、意外に
も紫外線照射のみでは全く過酸化されないのに対し、こ
のポルフィリンの出す一重項酸素が存在することによっ
てはじめて、しかも速やかに過酸化されることが明らか
になった。そして、この過酸化脂質によって表皮の過角
化が促進され、毛穴付近の角層が固く厚くなるため、毛
穴が詰まりやすくなりにきびの原因となることをはじめ
て突き止めた。In addition, epidermal lipids on the skin surface are unexpectedly not peroxidized at all by ultraviolet irradiation alone, but are peroxidized rapidly and only by the presence of singlet oxygen generated by the porphyrin. Was revealed. The lipid peroxide promoted hyperkeratosis of the epidermis, and the stratum corneum near the pores became firm and thick, so that it was found for the first time that pores were easily clogged and caused acne.
【0035】ところで、一重項酸素によって過酸化され
る表皮脂質成分の代表的なものがスクワレンであるか
ら、にきびの原因となるスクワレンの過酸化を防ぐため
には、スクワレンよりも一重項酸素と反応しやすい成分
を皮膚に適用すればよい。そして、ある化合物の一重項
酸素との反応のしやすさは反応速度定数と配合濃度によ
って決まるのであるから、両者を考慮して実際の皮膚外
用剤中での一重項酸素消去能力が求められる。By the way, since squalene is a typical epidermal lipid component which is peroxidized by singlet oxygen, in order to prevent peroxidation of squalene which causes acne, it reacts more with singlet oxygen than squalene. The easy ingredient may be applied to the skin. Since the ease with which single compound reacts with singlet oxygen is determined by the reaction rate constant and the compounding concentration, the singlet oxygen scavenging ability in an actual external preparation for skin is required in consideration of both.
【0036】本発明はこのような知見を元に、一定数以
上の一重項酸素消去能力を有する一重項酸素消去剤が皮
膚上のスクワレンの過酸化を抑制し、にきびの予防及び
改善に有効であるとして完成したものである。Based on these findings, the present invention provides a singlet oxygen scavenger having a certain number or more of singlet oxygen scavenging ability, which suppresses the peroxidation of squalene on the skin and is effective in preventing and improving acne. It is completed as it is.
【0037】また、そもそも一重項酸素の発生源が紫外
線によるポルフィリンの励起であることから、その原因
である紫外線を防御することが、一重項酸素の障害の防
御に有効であり、にきびの予防改善に非常に有効である
ことを見出したのである。Since the source of singlet oxygen is porphyrin excitation by ultraviolet light in the first place, it is effective to protect the ultraviolet light which is the cause thereof from the damage of singlet oxygen, and to prevent and improve acne. Was found to be very effective.
【0038】[0038]
【実施例】次に実施例および試験例を挙げて本発明を更
に詳細に説明するが、本発明はこれらになんら制約され
るものではない。EXAMPLES The present invention will be described in more detail with reference to the following Examples and Test Examples, which should not be construed as limiting the invention thereto.
【0039】試 験 例 1 一重項酸素消去能力の測定:特開平7−159325号
に開示の一重項酸素検出装置を用い、表1に示す試験薬
剤*について、下記のようにして一重項酸素消去速度定
数を測定した。すなわち、対照試料としてローズベンガ
ル100μM溶液を用い、これをフローセル中20mL
/分の速度で循環させた。このセルにUVA波長のレー
ザー光を照射した。この照射により生ずる発光スペクト
ルは1268nmに一重項酸素由来のピークを有するの
で、この対照試料の発光強度をIoとする。次に対照試
料中に試験薬剤を添加して同様の操作を行い、得られた
発光強度をIsとした。試験薬剤の配合濃度(Cs)に
対する発光強度の比Io/Isをプロットし、下のスター
ン・ボルマーの式(1)、 Io/Is = 1+kq・τ・Cs……(1) τ : 一重項酸素の寿命(溶媒によって異なる定数) Cs: 試験薬剤の配合濃度 により一重項酸素消去速度定数(kq)を求めた。実際
の一重項酸素消去能力は式(2)、 一重項酸素消去能力(s−1)=kq(g−1・L・s−1)× Cs(g・L−1)……(2) により、一重項酸素消去速度定数に実際の配合濃度をか
けて求められる。なお、試験薬剤の濃度(Cs)は固形
物濃度(g・L−1)で調製した。Test Example 1 Measurement of Singlet Oxygen Scavenging Ability: Using the singlet oxygen detecting device disclosed in Japanese Patent Application Laid-Open No. 7-159325, singlet oxygen scavenging was performed for test drugs * shown in Table 1 as follows. The rate constant was measured. That is, a 100 μM solution of Rose Bengal was used as a control sample, and this was added to a flow cell in 20 mL
/ Min. The cell was irradiated with UVA wavelength laser light. Since the emission spectrum generated by this irradiation has a peak derived from singlet oxygen at 1268 nm, the emission intensity of this control sample is defined as Io. Next, the same operation was performed by adding the test agent to the control sample, and the obtained luminescence intensity was defined as Is. The ratio Io / Is of the luminescence intensity to the compound concentration (Cs) of the test agent is plotted, and the following Stern-Volmer equation (1), Io / Is = 1 + kq · τ · Cs (1) τ: singlet oxygen Lifetime (constant depending on the solvent) Cs: The singlet oxygen elimination rate constant (kq) was determined from the compounding concentration of the test drug. The actual singlet oxygen scavenging ability is expressed by the following equation (2): Singlet oxygen scavenging ability (s −1 ) = kq (g− 1 · L · s −1 ) × Cs (g · L −1 ) (2) Is calculated by multiplying the singlet oxygen elimination rate constant by the actual compounding concentration. In addition, the concentration (Cs) of the test drug was adjusted to a solid concentration (g · L −1 ).
【0040】* 試験薬剤のうち、植物抽出物は次のよう
にして調製した。まず、各生薬を乾燥させ細切する。こ
の細切した生薬10重量部に50%エチルアルコール水
溶液100重量部を加え、室温にて時々攪拌しながら3
日間抽出した後、濾過して各抽出物を得た。* Among the test drugs, a plant extract was prepared as follows. First, each crude drug is dried and cut into small pieces. 100 parts by weight of a 50% aqueous solution of ethyl alcohol is added to 10 parts by weight of the cut crude drug, and 3
After extraction for days, each extract was obtained by filtration.
【0041】各試験薬剤の一重項酸素消去能力を評価し
た結果を、表1に示す。なお、一重項酸素消去能力は下
記3段階に評価した。Table 1 shows the results of evaluating the singlet oxygen scavenging ability of each test drug. The singlet oxygen scavenging ability was evaluated on the following three levels.
【0042】 ( 評価基準 ) 評 価 : 評 価 内 容 ◎ : 一重項酸素消去能力が 1000s−1以上のもの。 ○ : 一重項酸素消去能力が 50s−1以上、1000s−1 未満のもの。 × : 一重項酸素消去能力が 50s−1未満のもの。(Evaluation Criteria) Evaluation: Evaluation contents ◎: Singlet oxygen scavenging ability of 1000 s −1 or more. :: Singlet oxygen scavenging ability of 50 s −1 or more and less than 1000 s −1 . ×: Singlet oxygen scavenging ability of less than 50 s −1 .
【0043】( 結 果 )(Result)
【表1】 [Table 1]
【0044】表1の結果から明らかなごとく、A1〜A
24の各試験薬剤は高い一重項酸素消去能力を有するこ
とが認められ、これらを配合した皮膚外用剤に、アクネ
菌が産生するポルフィリンから発生する一重項酸素によ
るにきびの予防や改善効果があると判断された。As is clear from the results in Table 1, A1 to A
Each of the 24 test agents was found to have high singlet oxygen scavenging ability, and a skin external preparation containing these compounds had the effect of preventing and improving acne due to singlet oxygen generated from porphyrin produced by P. acnes. It was judged.
【0045】実 施 例 1 乳 液:以下に示す組成及び下記製法で乳液を調製し、
にきび予防および改善効果を調べた。この結果を表2に
示す。 ( 処 方 ) (%) (1)ポリオキシエチレン(10E.O.) 1.0 ソルビタンモノステアレート (2)ポリオキシエチレン(60E.O.) 0.5 ソルビットテトラオレエート (3)グリセリルモノステアレート 1.0 (4)ステアリン酸 0.5 (5)ベヘニルアルコール 0.5 (6)スクワラン 5.0 (7)防腐剤 0.1 (8)カルボキシビニルポリマー 0.1 (9)水酸化ナトリウム 0.05 (10)エチルアルコール 5.0 (11)精製水 残 量 (12)香料 適 量 (13)試験薬剤A1〜A30 (表2記載の種類および量)Example 1 Emulsion: An emulsion was prepared by the following composition and the following method.
The effects of acne prevention and improvement were investigated. Table 2 shows the results. (Preparation) (%) (1) Polyoxyethylene (10EO) 1.0 Sorbitan monostearate (2) Polyoxyethylene (60EO) 0.5 Sorbit tetraoleate (3) Glyceryl mono Stearate 1.0 (4) Stearic acid 0.5 (5) Behenyl alcohol 0.5 (6) Squalane 5.0 (7) Preservative 0.1 (8) Carboxyvinyl polymer 0.1 (9) Sodium hydroxide 0.05 (10) Ethyl alcohol 5.0 (11) Residual amount of purified water (12) Appropriate amount of perfume (13) Test drugs A1 to A30 (types and amounts described in Table 2)
【0046】( 製 法 ) A. 成分(1)〜(6)を加熱混合し、70℃に保つ。 B. 成分(9)と(11)の一部を加熱混合し、70℃
に保つ。 C. BにAを加えて混合し、均一に乳化する。 D. Cを冷却後(11)の残部に溶かした(7)、
(8)、(12)および(10)に溶かした(13)を
加え、均一に混合して乳液を得た。(Preparation Method) A. Components (1) to (6) are mixed by heating and kept at 70 ° C. B. Heat and mix a part of components (9) and (11),
To keep. C. Add A to B, mix and emulsify uniformly. D. C was dissolved in the remainder of (11) after cooling (7),
(13) dissolved in (8), (12) and (10) were added and mixed uniformly to obtain an emulsion.
【0047】( 試験方法 )被験乳液1品につき22歳
から40歳の女性15名をパネルとし、毎日、朝と夜の
2回、洗顔後に被験乳液の適量を顔面に塗布した。12
週間塗布を行い、塗布によるにきび改善効果の有効性
を、以下の3ランクで判断し、下記評価基準によって評
価した。(Test Method) An appropriate amount of the test emulsion was applied to the face after washing the face twice daily in the morning and at night, using a panel of 15 women 22 to 40 years old for each test emulsion. 12
Weekly application was performed, and the effectiveness of the acne improvement effect of the application was judged by the following three ranks and evaluated according to the following evaluation criteria.
【0048】( 有効性ランク ) 有 効 … … にきびが出来にくくなった。にきびが
目立たなくなった。 やや有効 … … にきびがやや出来にくくなった。にき
びがあまり目立たなくなった。 無 効 … … 使用前と変化なし。(Effectiveness rank) Effective ... Acne became difficult to be formed. Acne is no longer noticeable. Somewhat effective…… Acne became somewhat difficult. Acne has become less noticeable. Ineffective ...... No change from before use.
【0049】 ( 評価基準 ) 評 価 : 評 価 内 容 ◎ : 有効とやや有効を合わせた人数が10名以上。 ○ : 有効とやや有効を合わせた人数が5名から9名。 △ : 有効とやや有効を合わせた人数が1名から4名。 × : 有効とやや有効を合わせた人数が0名。(Evaluation Criteria) Evaluation: Evaluation content ◎: The number of people who combined the effectiveness with the effectiveness was 10 or more. ○: The number of people who combined the validity and the validity was 5 to 9 people. △: The number of people who were effective and slightly effective was 1 to 4 people. ×: The number of people who combined the validity and the validity was 0.
【0050】( 結 果 )(Result)
【表2】 [Table 2]
【0051】表2に示される如く、表1で一重項酸素消
去能力が50s−1以上になった一重項酸素消去剤を配
合した皮膚外用剤は、これらを皮膚に適用することによ
り、にきびの防止、改善することができ、美しい肌とす
ることが明らかとなった。特に、好ましくは1000s
−1以上になるように一重項酸素消去剤を配合した皮膚
外用剤は、その効果が優れていた。As shown in Table 2, a skin external preparation containing a singlet oxygen scavenger having a singlet oxygen scavenging ability of 50 s -1 or more in Table 1 was applied to the skin to obtain acne. It can be prevented and improved, and it is clear that the skin is beautiful. In particular, preferably 1000s
The external preparation for skin containing a singlet oxygen scavenger so as to be −1 or more was excellent in its effect.
【0052】実 施 例 2 乳 液 :下記の基本組成に、表3で示す種類および量
の一重項酸素消去剤や紫外線防止剤、美白剤、抗炎症
剤、殺菌剤、細胞賦活剤などの薬剤を添加し、下記製法
で乳液を調製して、美肌効果を調べた。この結果も表3
に示す。なお、基本組成および表3に示された配合量
は、最終製品である乳液での配合量である。Example 2 Emulsion: Emulsions having the following basic composition and types and amounts of singlet oxygen scavengers, UV inhibitors, whitening agents, anti-inflammatory agents, bactericides, cell activators, etc. Was added, and an emulsion was prepared by the following method, and the skin effect was examined. This result is also shown in Table 3.
Shown in The basic composition and the amounts shown in Table 3 are the amounts in the emulsion as the final product.
【0053】 ( 基本組成 ) (%) (1)ポリオキシエチレン(60E.O.)ソルビタン 1.0 モノステアレート (2)ポリオキシエチレン(60E.O.)ソルビット 0.5 テトラオレエート (3)グリセリンモノステアレート 1.0 (4)ステアリン酸 0.5 (5)ベヘニルアルコール 0.5 (6)スクワラン 5.0 (7)防腐剤 0.1 (8)カルボキシビニルポリマー 0.1 (9)水酸化ナトリウム 0.05 (10)エチルアルコール 5.0 (11)精製水 残 量 (12)香 料 適 量(Basic composition) (%) (1) polyoxyethylene (60E.O.) sorbitan 1.0 monostearate (2) polyoxyethylene (60E.O.) sorbit 0.5 tetraoleate (3) ) Glycerin monostearate 1.0 (4) Stearic acid 0.5 (5) Behenyl alcohol 0.5 (6) Squalane 5.0 (7) Preservative 0.1 (8) Carboxyvinyl polymer 0.1 (9) Sodium hydroxide 0.05 (10) Ethyl alcohol 5.0 (11) Residual amount of purified water (12) Appropriate amount of flavor
【0054】( 組成及び結果 )(Composition and Results)
【表3】 [Table 3]
【0055】( 製 法 ) A. 成分(1)〜(6)を加熱混合し、70℃に保つ。 B. 成分(9)と(11)の一部を加熱混合し、70℃
に保つ。 C. BにAを加えて混合し、均一に乳化する。 D. Cを冷却後(11)の残部に溶かした(7)、
(8)、(12)および表3の(13)〜(40)の成
分を(10)に溶かして加え、均一に混合して乳液を得
た。(Preparation Method) A. Components (1) to (6) are mixed by heating and maintained at 70 ° C. B. Heat and mix a part of components (9) and (11),
To keep. C. Add A to B, mix and emulsify uniformly. D. C was dissolved in the remainder of (11) after cooling (7),
(8), (12) and the components (13) to (40) in Table 3 were dissolved in (10) and added, followed by uniform mixing to obtain an emulsion.
【0056】( 試験方法 )被験乳液について、実施例
1と同様にして評価した。(Test Method) The test emulsion was evaluated in the same manner as in Example 1.
【0057】表3の結果に示される如く、一重項酸素消
去能力が50s−1以上となるよう一重項酸素消去剤を
配合する皮膚外用剤は、これを紫外線防止剤や、美白
剤、抗炎症剤、殺菌剤、細胞賦活剤と併用し、皮膚に適
用することにより、一重項酸素消去剤を単独で配合した
外用剤を適用した場合より更に優れたにきびの防止、改
善効果を発揮し、透明感のある美しい肌とすることが明
らかとなった。As shown in the results in Table 3, a skin external preparation containing a singlet oxygen scavenger so as to have a singlet oxygen scavenging ability of 50 s -1 or more was treated with an ultraviolet ray inhibitor, a whitening agent, and an anti-inflammatory agent. When applied to the skin in combination with an agent, a bactericide, and a cell activator, it exerts an even better anti-acne prevention and improvement effect than when an external preparation containing a singlet oxygen scavenger alone is applied, and is transparent. It became clear that the skin had a beautiful feeling.
【0058】 実 施 例 3 化 粧 水: ( 処 方 ) (%) (1)グリセリン 5.0 (2)1,3−ブチレングリコール 6.5 (3)ポリオキシエチレン(20E.O.) 1.2 ソルビタンモノラウリン酸エステル (4)エチルアルコール 8.0 (5)マイカイカ抽出物*1 0.5 (6)甘草抽出物*1 0.1 (7)シソ抽出物*1 0.1 (8)セリン*2 0.01 (9)防腐剤 適 量 (10)香料 適 量 (11)精製水 残 量 *1 試験例1の方法にて調製したもの *2 協和発酵社製Example 3 Cosmetic Water: (Preparation) (%) (1) Glycerin 5.0 (2) 1,3-butylene glycol 6.5 (3) Polyoxyethylene (20EO) 1 .2 Sorbitan monolaurate (4) Ethyl alcohol 8.0 (5) Green squid extract * 1 0.5 (6) Licorice extract * 1 0.1 (7) Perilla extract * 1 0.1 (8) Serine * 2 0.01 (9) Preservative appropriate amount (10) Flavor appropriate amount (11) Purified water residue * 1 Prepared by the method of Test Example 1 * 2 Kyowa Hakko Co., Ltd.
【0059】( 製 法 ) A. 成分(3)、(4)、(9)及び(10)を混合溶
解する。 B. 成分(1)、(2)、(5)〜(8)及び(11)
を混合溶解する。 C. AとBを混合して均一にし、化粧水を得た。(Production method) A. Components (3), (4), (9) and (10) are mixed and dissolved. B. Components (1), (2), (5) to (8) and (11)
Are mixed and dissolved. C. A and B were mixed and made uniform to obtain a lotion.
【0060】 実 施 例 4 ク リ ー ム : ( 処 方 ) (%) (1)ミツロウ 6.0 (2)セタノール 5.0 (3)還元ラノリン 5.0 (4)スクワラン 30.0 (5)親油型モノステアリン酸 グリセリル 4.0 (6)ポリオキシエチレンソルビタン モノラウレート(20E.O.) 2.0 (7)サンペンズ抽出物*1 0.5 (8)アロエ抽出物*1 0.1 (9)オウゴン抽出物*1 0.01 (10)乳酸菌醗酵代謝物*2 0.1 (11)防腐剤 適 量 (12)香料 適 量 (13)精製水 残 量 *1 試験例1の方法にて調製したもの *2 一丸ファルコス社製Example 4 Cream: (Preparation) (%) (1) Beeswax 6.0 (2) Cetanol 5.0 (3) Reduced Lanolin 5.0 (4) Squalane 30.0 (5) ) Lipophilic glyceryl monostearate 4.0 (6) Polyoxyethylene sorbitan monolaurate (20EO) 2.0 (7) Sampens extract * 1 0.5 (8) Aloe extract * 10 .1 (9) Ougon extract * 1 0.01 (10) Lactic acid bacteria fermentation metabolite * 2 0.1 (11) Suitable amount of preservative (12) Suitable amount of flavor (13) Residual amount of purified water * 1 Test example 1 * 2 Manufactured by Ichimaru Falcos
【0061】( 製 法 ) A. 成分(1)〜(6)および(11)を混合し、加熱
して70℃に保つ。 B. 成分(13)を加熱して70℃に保つ。 C. AにBを加え、(7)〜(10)及び(12)を混
合した後、冷却してクリームを得た。(Preparation method) A. Components (1) to (6) and (11) are mixed and heated to 70 ° C. B. Heat component (13) to 70 ° C. C. B was added to A, (7) to (10) and (12) were mixed, and then cooled to obtain a cream.
【0062】実施例3で得た化粧水および実施例4で得
たクリームは、いずれも経時安定性に優れ、皮膚に適用
することにより、にきびを予防および改善し透明感のあ
る美しい肌にするものであった。Both the lotion obtained in Example 3 and the cream obtained in Example 4 have excellent stability over time, and when applied to the skin, can prevent and improve acne and provide clear and beautiful skin. Was something.
【0063】 実 施 例 5 軟 膏 : ( 処 方 ) (%) (1)ステアリン酸 18.0 (2)セタノール 4.0 (3)トリエタノールアミン 2.0 (4)グリセリン 5.0 (5)羅漢果抽出物*1 1.0 (6)海藻抽出物*2 0.5 (7)カミツレ抽出物*1 0.2 (8)精製水 残 量 *1 試験例1の方法で調製したもの *2 テクノーブル社製Example 5 Ointment: (preparation) (%) (1) Stearic acid 18.0 (2) Cetanol 4.0 (3) Triethanolamine 2.0 (4) Glycerin 5.0 (5) ) Arhat extract * 1 1.0 (6) Seaweed extract * 2 0.5 (7) Chamomile extract * 1 0.2 (8) Residual water * 1 Prepared by the method of Test Example 1 * 2 Technoble
【0064】( 製 法 ) A. 成分(3)、(4)及び(8)の一部を加熱混合
し、75℃に保つ。 B. 成分(1)、(2)を加熱混合し、75℃に保つ。 C. AをBに徐々に加える。 D. Cを冷却しながら(8)の残部で溶解した(5)〜
(7)を加え、軟膏を得た。(Preparation Method) A. A part of the components (3), (4) and (8) is heated and mixed and kept at 75 ° C. B. Components (1) and (2) are mixed by heating and kept at 75 ° C. C. Add A slowly to B. D. Dissolved in the remainder of (8) while cooling C (5)-
(7) was added to obtain an ointment.
【0065】実施例5で得た軟膏は経時安定性に優れ、
皮膚に適用することにより、にきびを防止し、透明感の
ある美しい肌にするものであった。The ointment obtained in Example 5 has excellent stability over time,
By applying to the skin, acne was prevented, and the skin was made clear and beautiful.
【0066】 実 施 例 6 パ ッ ク : ( 処 方 ) (%) (1)ポリビニルアルコール 20.0 (2)エチルアルコール 20.0 (3)グリセリン 5.0 (4)カオリン 6.0 (5)茶抽出物*1 0.1 (6)ジユ抽出物*1 0.2 (7)コムギ抽出物*1 0.1 (8)防腐剤 0.2 (9)香料 0.1 (10)精製水 残 量 *1 試験例1の方法で調製したものExample 6 Pack: (Preparation) (%) (1) Polyvinyl alcohol 20.0 (2) Ethyl alcohol 20.0 (3) Glycerin 5.0 (4) Kaolin 6.0 (5) ) Tea extract * 1 0.1 (6) Jiyu extract * 1 0.2 (7) Wheat extract * 1 0.1 (8) Preservative 0.2 (9) Flavor 0.1 (10) Purification Water residue * 1 Prepared by the method of Test Example 1.
【0067】( 製 法 ) A. 成分(1)、(3)、(4)及び(10)を混合
し、70℃に加熱し、撹拌する。 B. 成分(2)及び(8)を混合する。 C. 上記Bを先のAに加え、混合した後、冷却して
(5)〜(7)及び(9)を均一に分散してパックを得
た。(Preparation Method) A. Components (1), (3), (4) and (10) are mixed, heated to 70 ° C., and stirred. B. Mix components (2) and (8). C. The above B was added to the above A, mixed, cooled, and (5) to (7) and (9) were uniformly dispersed to obtain a pack.
【0068】実施例6のパックは経時安定性に優れ、皮
膚に適用することにより、にきびを防止し、透明感のあ
る美しい肌にするものであった。The pack of Example 6 was excellent in stability over time and, when applied to the skin, prevented acne and gave clear and beautiful skin.
【0069】 実 施 例 7 リキッドファンデーション: ( 処 方 ) (%) (1)ラノリン 7.0 (2)流動パラフィン 5.0 (3)ステアリン酸 2.0 (4)セタノール 1.0 (5)パラメトキシケイ皮酸 3.0 −2−エチルヘキシル (6)グリセリン 5.0 (7)トリエタノールアミン 1.0 (8) カルボキシメチルセルロース 0.7 (9) 精製水 残 量 (10) 酸化チタン 8.0 (11) 微粒子酸化チタン 2.0 (12) 酸化亜鉛 5.0 (13)マイカ 15.0 (14)タルク 6.0 (15)着色顔料 6.0 (16)メリッサ抽出物*1 0.01 (17)オウバク抽出物*1 0.5 (18)ヨモギ抽出物*1 0.1 (19)香料 適 量 *1 試験例1の方法で調製したものExample 7 Liquid foundation: (Preparation) (%) (1) Lanolin 7.0 (2) Liquid paraffin 5.0 (3) Stearic acid 2.0 (4) Cetanol 1.0 (5) Paramethoxycinnamic acid 3.0-2-ethylhexyl (6) Glycerin 5.0 (7) Triethanolamine 1.0 (8) Carboxymethylcellulose 0.7 (9) Remaining purified water (10) Titanium oxide 8. 0 (11) Fine particle titanium oxide 2.0 (12) Zinc oxide 5.0 (13) Mica 15.0 (14) Talc 6.0 (15) Color pigment 6.0 (16) Melissa extract * 1 0.0 01 (17) Mackerel extract * 1 0.5 (18) Artemisia extract * 1 0.1 (19) Appropriate amount of flavor * 1 Prepared by the method of Test Example 1
【0070】( 製 法 ) A. 成分(1)〜(5)を混合溶解する。 B. Aに成分(10)〜(15)を加え、均一に混合
し、70℃に保つ。 C. 成分(6)〜(9)を均一に溶解し、70℃に保
つ。 D. BにCを添加して、均一に乳化する。 E. Dを冷却後、成分(16)〜(19)を添加してリ
キッドファンデーションを得た。(Production Method) A. Components (1) to (5) are mixed and dissolved. B. Add components (10) to (15) to A, mix uniformly, and keep at 70 ° C. C. Components (6) to (9) are uniformly dissolved and kept at 70 ° C. D. Add C to B and emulsify uniformly. After cooling E.D, components (16) to (19) were added to obtain a liquid foundation.
【0071】実施例7で得られたリキッドファンデーシ
ョンは経時安定性に優れ、皮膚に適用することにより、
にきびを防止するものであった。The liquid foundation obtained in Example 7 has excellent stability over time, and can be applied to the skin to
It was to prevent acne.
【0072】[0072]
【発明の効果】以上のごとく、一定以上の一重項酸素消
去能力を有する一重項酸素消去剤を含有する本発明の皮
膚外用剤は、その一重項酸素消去能力によりアクネ菌の
産生するポルフィリンから発生する一重項酸素を消去
し、にきびの予防や改善に有効なものである。As described above, the external preparation for skin of the present invention containing a singlet oxygen scavenger having a certain amount or more of singlet oxygen scavenging ability is generated from porphyrin produced by acne bacteria due to its singlet oxygen scavenging ability. It is effective in eliminating singlet oxygen and preventing or improving acne.
【0073】さらに、上記一重項酸素消去剤を紫外線吸
収剤や、殺菌剤、抗炎症剤、美白剤、細胞賦活剤と組み
合わせることにより、にきび対して高い予防効果及び改
善効果を有すると共に、にきび跡の色素沈着改善等に有
効な皮膚外用剤とすることができる。 以 上Further, by combining the above singlet oxygen scavenger with an ultraviolet absorbent, a bactericide, an anti-inflammatory agent, a whitening agent, and a cell activator, it has a high preventive and ameliorating effect on acne and also has acne scars. It can be used as an external preparation for skin which is effective for improving pigmentation. that's all
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61K 31/122 A61K 31/122 31/195 31/195 31/255 31/255 31/352 31/352 31/355 31/355 31/405 31/405 31/4172 31/4172 31/662 31/662 31/7004 31/7004 31/7048 31/7048 35/78 35/78 C A61P 17/10 A61P 17/10 39/06 39/06 (72)発明者 高山 明美 東京都北区栄町48番18号 株式会社コーセ ー研究本部内 Fターム(参考) 4C083 AA032 AA082 AA111 AA112 AB032 AB212 AB242 AB442 AC011 AC012 AC022 AC072 AC102 AC122 AC211 AC212 AC242 AC342 AC422 AC542 AC581 AC582 AC791 AC792 AC841 AC842 AC851 AC852 AD092 AD112 AD201 AD202 AD272 AD512 AD661 AD662 CC04 CC05 CC07 CC12 DD23 DD31 EE14 4C086 AA01 AA02 BA08 BA09 BC14 BC38 EA01 EA11 MA01 MA03 MA04 MA05 MA63 NA14 ZA89 ZC37 4C088 AB11 BA08 MA63 NA14 ZA89 ZC37 4C206 AA01 AA02 BA02 CB25 FA53 JA27 JA62 MA01 MA03 MA04 MA05 MA83 NA14 ZA89 ZC21 ZC37 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme court ゛ (Reference) A61K 31/122 A61K 31/122 31/195 31/195 31/255 31/255 31/352 31/352 31 / 355 31/355 31/405 31/405 31/4172 31/4172 31/662 31/662 31/7004 31/7004 31/7048 31/7048 35/78 35/78 C A61P 17/10 A61P 17/10 39/06 39/06 (72) Inventor Akemi Takayama 48-18 Sakaemachi, Kita-ku, Tokyo F-term in Koseh Research Laboratories (reference) 4C083 AA032 AA082 AA111 AA112 AB032 AB212 AB242 AB442 AC011 AC012 AC022 AC072 AC102 AC122 AC211 AC212 AC242 AC342 AC422 AC542 AC581 AC582 AC791 AC792 AC841 AC842 AC851 AC852 AD092 AD112 AD201 AD202 AD272 AD512 AD661 AD662 CC04 CC05 CC07 CC12 DD23 DD31 EE14 4C086 AA01 AA02 BA08 BA09 BC14 BC38 EA01 EA11 MA01 MA03 MA04 MA05 Z14 ZA89 ZC37 4C2 06 AA01 AA02 BA02 CB25 FA53 JA27 JA62 MA01 MA03 MA04 MA05 MA83 NA14 ZA89 ZC21 ZC37
Claims (4)
上となる量の一重項酸素消去剤を含有することを特徴と
するにきび用皮膚外用剤。1. A skin external preparation for acne, comprising an amount of a singlet oxygen scavenger having a singlet oxygen scavenging ability of 50 s -1 or more.
量の一重項酸素消去剤 (B)紫外線防止剤の一種又は二種以上を含有すること
を特徴とするにきび用皮膚外用剤。2. The following components (A) and (B): (A) a singlet oxygen scavenger having an amount of 50 s -1 or more as a singlet oxygen scavenging ability ; and (B) one or more kinds of ultraviolet inhibitors. A skin external preparation for acne, characterized by containing.
選ばれる薬剤の一種又は二種以上を含有する請求項第1
項または第2項記載のにきび用皮膚外用剤。3. The composition according to claim 1, further comprising (C) (C) one or more drugs selected from whitening agents, anti-inflammatory agents, bactericides and cell activators.
Item 3. An external preparation for acne according to Item 2 or 2.
導体、クエルセチン、β−カロチン、アスタキサンチ
ン、ゼアキサンチン、ビタミンE及びその誘導体並びに
それらの塩、エリソルビン酸、ヒスチジン、トリプトフ
ァン、チロシン、メチオニン、シスチン、ヒポタウリン、チ
オタウリン、ニンジン抽出物、マイカイカ抽出物、サン
ペンズ抽出物、メリッサ抽出物、ヤシャジツ抽出物、羅
漢果抽出物、茶抽出物またはリン脂質から選ばれるもの
である請求項第1項ないし第3項の何れかの項記載のに
きび用皮膚外用剤。4. The method according to claim 1, wherein the singlet oxygen scavenger is rutin or a derivative thereof, quercetin, β-carotene, astaxanthin, zeaxanthin, vitamin E or a derivative thereof and a salt thereof, erythorbic acid, histidine, tryptophan, tyrosine, methionine, cystine, hypotaurine. 4. The extract according to claim 1, wherein the extract is selected from the group consisting of thiotaurine, carrot extract, squid extract, sampens extract, melissa extract, yasatsutsu extract, arhat extract, tea extract and phospholipid. The skin external preparation for acne according to the above item.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000098285A JP4070935B2 (en) | 2000-03-31 | 2000-03-31 | Acne skin external preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000098285A JP4070935B2 (en) | 2000-03-31 | 2000-03-31 | Acne skin external preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001288035A true JP2001288035A (en) | 2001-10-16 |
| JP4070935B2 JP4070935B2 (en) | 2008-04-02 |
Family
ID=18612786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000098285A Expired - Lifetime JP4070935B2 (en) | 2000-03-31 | 2000-03-31 | Acne skin external preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4070935B2 (en) |
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004161641A (en) * | 2002-11-12 | 2004-06-10 | Nonogawa Shoji Kk | Cosmetic |
| JP2004262862A (en) * | 2003-03-03 | 2004-09-24 | Naris Cosmetics Co Ltd | External preparation for skin |
| JP2005053785A (en) * | 2003-05-20 | 2005-03-03 | Nippon Menaade Keshohin Kk | External preparation |
| WO2006062740A3 (en) * | 2004-11-22 | 2006-08-10 | Nu Tein Co Inc | Topical skin patch containing xanthophylls |
| JP2006290832A (en) * | 2005-04-13 | 2006-10-26 | Noevir Co Ltd | Topical skin preparation |
| WO2007029730A1 (en) * | 2005-09-06 | 2007-03-15 | Meiji Dairies Corporation | Amino acid composition for prevention or treatment of senile anemia |
| JP2007516185A (en) * | 2003-07-07 | 2007-06-21 | トレル、 ジャン ノエル | Use of antioxidants in dermatological and / or cosmetic compositions |
| JP2008120781A (en) * | 2006-11-13 | 2008-05-29 | Saraya Kk | External preparation for skin containing momordica grosvenori glycoside |
| JP2010037314A (en) * | 2008-08-08 | 2010-02-18 | Kao Corp | Hairdye composition |
| JP2010202617A (en) * | 2009-03-05 | 2010-09-16 | Kose Corp | Singlet oxygen eliminator, and skin care preparation and cosmetic containing the same |
| JP2011528377A (en) * | 2008-07-17 | 2011-11-17 | レヴィス,ジョージア | Methods and materials for the treatment of acne |
| WO2011009759A3 (en) * | 2009-07-23 | 2011-12-01 | Henkel Ag & Co. Kgaa | Use of dihydroquercetin and at least one amino acid to positively influence the natural pigmentation process |
| JP2012532926A (en) * | 2009-07-14 | 2012-12-20 | スンチョニャン ユニバーシティ インダストリー アカデミー コーポレイション ファウンデーション | Soap composition for acne treatment containing ginseng absolute essential oil |
| JP2013155158A (en) * | 2012-01-31 | 2013-08-15 | Increase Kenkyusho:Kk | Antimicrobial agent composition and method for producing the same |
| KR101308507B1 (en) * | 2011-07-07 | 2013-09-17 | (주)비알뷰티플레볼루션 | Acne therapeutics and sebum secernent inhibitor which comprise tryptophan, and kits for photodynamic therapy containing the same |
| JP2019129789A (en) * | 2018-02-01 | 2019-08-08 | 株式会社ノエビア | Anti-acne food, hair quality improving food or makeup applicability improving food |
| WO2022145108A1 (en) * | 2021-01-04 | 2022-07-07 | 国立研究開発法人国際農林水産業研究センター | Antioxidant and method for producing same |
| WO2023046961A1 (en) * | 2021-09-27 | 2023-03-30 | Givaudan Sa | Polyglycosylated rutin derivatives for reducing facial skin reactions |
| CN116492238A (en) * | 2023-04-23 | 2023-07-28 | 广州集妍化妆品科技有限公司 | Composition for preventing and treating acne and its application |
| JP2024034621A (en) * | 2022-09-01 | 2024-03-13 | 長谷川香料株式会社 | Pore improver |
| JP2024078511A (en) * | 2022-11-30 | 2024-06-11 | 長谷川香料株式会社 | Skin improvement agent |
-
2000
- 2000-03-31 JP JP2000098285A patent/JP4070935B2/en not_active Expired - Lifetime
Cited By (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004161641A (en) * | 2002-11-12 | 2004-06-10 | Nonogawa Shoji Kk | Cosmetic |
| JP2004262862A (en) * | 2003-03-03 | 2004-09-24 | Naris Cosmetics Co Ltd | External preparation for skin |
| JP2005053785A (en) * | 2003-05-20 | 2005-03-03 | Nippon Menaade Keshohin Kk | External preparation |
| JP2007516185A (en) * | 2003-07-07 | 2007-06-21 | トレル、 ジャン ノエル | Use of antioxidants in dermatological and / or cosmetic compositions |
| WO2006062740A3 (en) * | 2004-11-22 | 2006-08-10 | Nu Tein Co Inc | Topical skin patch containing xanthophylls |
| JP2008520735A (en) * | 2004-11-22 | 2008-06-19 | ニュー‐ティーン カンパニー,インク. | Topical skin patch |
| JP2006290832A (en) * | 2005-04-13 | 2006-10-26 | Noevir Co Ltd | Topical skin preparation |
| WO2007029730A1 (en) * | 2005-09-06 | 2007-03-15 | Meiji Dairies Corporation | Amino acid composition for prevention or treatment of senile anemia |
| JP5220415B2 (en) * | 2005-09-06 | 2013-06-26 | 株式会社明治 | Amino acid composition for preventing or treating senile anemia |
| JP2008120781A (en) * | 2006-11-13 | 2008-05-29 | Saraya Kk | External preparation for skin containing momordica grosvenori glycoside |
| JP2011528377A (en) * | 2008-07-17 | 2011-11-17 | レヴィス,ジョージア | Methods and materials for the treatment of acne |
| JP2010037314A (en) * | 2008-08-08 | 2010-02-18 | Kao Corp | Hairdye composition |
| JP2010202617A (en) * | 2009-03-05 | 2010-09-16 | Kose Corp | Singlet oxygen eliminator, and skin care preparation and cosmetic containing the same |
| JP2012532926A (en) * | 2009-07-14 | 2012-12-20 | スンチョニャン ユニバーシティ インダストリー アカデミー コーポレイション ファウンデーション | Soap composition for acne treatment containing ginseng absolute essential oil |
| WO2011009759A3 (en) * | 2009-07-23 | 2011-12-01 | Henkel Ag & Co. Kgaa | Use of dihydroquercetin and at least one amino acid to positively influence the natural pigmentation process |
| KR101308507B1 (en) * | 2011-07-07 | 2013-09-17 | (주)비알뷰티플레볼루션 | Acne therapeutics and sebum secernent inhibitor which comprise tryptophan, and kits for photodynamic therapy containing the same |
| JP2013155158A (en) * | 2012-01-31 | 2013-08-15 | Increase Kenkyusho:Kk | Antimicrobial agent composition and method for producing the same |
| JP2019129789A (en) * | 2018-02-01 | 2019-08-08 | 株式会社ノエビア | Anti-acne food, hair quality improving food or makeup applicability improving food |
| WO2022145108A1 (en) * | 2021-01-04 | 2022-07-07 | 国立研究開発法人国際農林水産業研究センター | Antioxidant and method for producing same |
| JP2022105458A (en) * | 2021-01-04 | 2022-07-14 | 国立研究開発法人国際農林水産業研究センター | Antioxidant and method for producing the same |
| JP7533892B2 (en) | 2021-01-04 | 2024-08-14 | 国立研究開発法人国際農林水産業研究センター | Antioxidant and its manufacturing method |
| WO2023046961A1 (en) * | 2021-09-27 | 2023-03-30 | Givaudan Sa | Polyglycosylated rutin derivatives for reducing facial skin reactions |
| JP2024034621A (en) * | 2022-09-01 | 2024-03-13 | 長谷川香料株式会社 | Pore improver |
| JP2024078511A (en) * | 2022-11-30 | 2024-06-11 | 長谷川香料株式会社 | Skin improvement agent |
| CN116492238A (en) * | 2023-04-23 | 2023-07-28 | 广州集妍化妆品科技有限公司 | Composition for preventing and treating acne and its application |
| CN116492238B (en) * | 2023-04-23 | 2024-07-30 | 广州集妍化妆品科技有限公司 | Composition for preventing and treating acne and its application |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4070935B2 (en) | 2008-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001288035A (en) | External preparation for skin for acne | |
| JP2000095663A (en) | Agent for external use containing plant extract | |
| JPH07309770A (en) | Mucopolysaccharide fragmentation inhibitor, active oxygen scavenger and cosmetics | |
| KR20000026159A (en) | Method for stabilizing an ascorbic acid, its derivatives and/or extract containing ascorbic acid for local application | |
| JPH09291011A (en) | Composition suitable for eternal use | |
| JPH07277939A (en) | Skin external preparation | |
| JP2001181173A (en) | Bleaching preparation for external use | |
| JPH09157153A (en) | Preparation for external use for skin | |
| JPH03153609A (en) | Skin-beautifying cosmetic | |
| KR100371028B1 (en) | Cosmetic composition containing Salvia militiorrhira Bge. extracts and polyethoxylated retinamide | |
| JP2001335497A (en) | Skin care preparation and skin care preparation composition | |
| JP6757130B2 (en) | A composition having an azulene compound, and a discoloration inhibitor and a discoloration prevention method for the azulene compound. | |
| JP7328957B2 (en) | External composition containing ascorbic acid and/or its salt | |
| JPH10330217A (en) | Skin whitening preparation for external use | |
| JP2003267854A (en) | Bleaching cosmetic | |
| JPS61176510A (en) | Skin-beautifying cosmetic | |
| JP2002370962A (en) | Bleaching preparation and cosmetic for preventing and improving aging of skin | |
| JP2781982B2 (en) | External preparation for skin | |
| JPH01249714A (en) | Skin cosmetic | |
| JP2002020232A (en) | Skin care preparation and skin care composition | |
| JPH0692833A (en) | Skin external agent | |
| JPH0193509A (en) | Skin drug for external use | |
| JPH11292737A (en) | Immunopotentiation agent | |
| JPS60116616A (en) | Cosmetic | |
| JP2001278775A (en) | Skin care preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050819 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20060922 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061024 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061222 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070529 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070727 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20070727 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20071225 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080116 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4070935 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110125 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140125 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |